Moderna, Inc. and Immatics N.V. announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.01 USD | +2.35% | -1.96% | -4.94% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
108 USD | +1.69% | +6.47% | 41.34B | ||
10.01 USD | +2.35% | -1.96% | 1.03B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.94% | 1.03B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IMTX Stock
- News Immatics N.V.
- Moderna, Inc. and Immatics N.V. Announces Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics